Wockhardt Limited
Investor Presentation By
- Dr. Murtaza Khorakiwala
Managing Director Q1FY16
Wockhardt Limited Investor Presentation By Dr. Murtaza Khorakiwala - - PowerPoint PPT Presentation
Wockhardt Limited Investor Presentation By Dr. Murtaza Khorakiwala Managing Director Q1FY16 Safe Harbor Statement Except for historical information contained herein, statements in this communication, which include words or phrases such
Investor Presentation By
Managing Director Q1FY16
words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “August”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions August constitute “forward looking statements”. These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other
reflect events or circumstances after the date thereof.
Investor Presentation August 2015 2
ROW operations Wockhardt Direct
USA UK, Ireland, France, Switz. India
Mexico
Investor Presentation August 2015 4
Direct Operations in India, USA and Europe
Multi Ethnic workforce from 21 different Nationalities
UK Ireland
Investor Presentation August 2015 5
Manufacturing Locations globally
Ankleshwar Daman (2 Plants) Aurangabad (5 Plants) Baddi Chicago
Formulations APIs 9 sites in India
Investor Presentation August 2015 6
worldwide
Investor Presentation August 2015 8
in July, 2015 and no 483 has been issued to the company.
facilities continues to be in place.
4873 during the quarter. Previously 2 of its drug WCK 771 and WCK 2349 received QIDP
extensions to the drug patents in USA. Wockhardt is the only Indian company to receive QIDP status for its NCE products.
Oxycodone is used extensively in management of pain, especially in opioid tolerant patients.
granted 26 patents during the quarter taking the cumulative patents granted to 367.
Investor Presentation August 2015 10
Rs.crore Growth of 15% in Q1FY16 over Q1FY15
Investor Presentation August 2015 11
Rs.crore Growth of 165% in Q1FY16 over Q1FY15
Investor Presentation August 2015 12
Rs.crore Growth of 470% in Q1FY16 over Q1FY15
Investor Presentation August 2015 13
Growth of 31% in Q1FY16 over Q1FY15
Investor Presentation August 2015 14
& 1 approval received cumulative ANDA’s pending for approval is 73.
287 227
400
Q1-FY15 Q1-FY16
USA
Rs.cr.
$48 $36
UK Operations
Q1FY16.
Q1FY16.
Investor Presentation August 2015 15
Ireland Operations
Q1FY16.
237 368
120 170 220 270 320 370 420 Q1-FY15 Q1-FY16
UK
Rs.cr. £ 23 £ 37 44 39
36 37 38 39 40 41 42 43 44 Q1-FY15 Q1-FY16
Ireland
Rs.cr. € 5 € 6
India.
47% in Q1FY16.
Investor Presentation August 2015 16
295 India 375 India
66 EM
97 EM 100 200 300 400 500
Q1FY15 Q1FY16
India & Emerging Markets (EM)
Rs.cr.
Investor Presentation August 2015 17
For investor updates and communication please visit www.wockhardt.com For Information please contact Arun Khatanhar Tel.: +91 22 71596228 Akhatanhar@wockhardt.com